Fig 3.
(A) Progression-free (PFS) and (B) overall survival (OS) based on EGFR mutation (mut) in arm A (erlotinib alone). (C) PFS and (D) OS based on EGFR mut in arm B (erlotinib plus carboplatin and paclitaxel). HR, hazard ratio; WT, wild type.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.